全球抗癫痫药物市场：市场规模、市场占有率、成长率、产业分析、依类型、应用和地区划分的分析、未来预测（2026-2034）

抗癫痫药物 (AED) 市场成长因子

由于全球癫痫患者人数不断增加、人们对神经系统疾病的认识不断提高以及药物研发的持续进步，全球抗癫痫药物 (AED) 市场正经历稳步增长。根据 Fortune Business Insights 预测，该市场规模预计将在 2025 年达到 178.2 亿美元，从 2026 年的 185.7 亿美元增长到 2034 年的 275.7 亿美元，在预测期（2026-2034 年）内复合年增长率 (CAGR) 为 5.10%。

截至 2025 年，北美在全球 AED 市场占主导地位，市占率高达 48.40%。 高诊断率、强有力的医疗保险政策以及新癫痫药物频繁获得监管部门批准，都为市场成长提供了支持。

市场驱动因素

癫痫以反覆发作、意识丧失和行为障碍为特征，是世界上最常见的神经系统疾病之一。根据世界卫生组织（WHO，2023）统计，全球约有5,000万人患有癫痫，其中约80%生活在中低收入国家（LMIC）。如此高的疾病负担使得对有效、长期抗癫痫疗法的需求庞大。

癫痫盛行率的不断上升给医疗保健系统带来了沉重的经济负担，促使各国政府和製药公司致力于扩大治疗的可近性。为此，市场参与者正专注于开发疗效更佳、副作用更小的标靶药物，这正积极推动市场成长。

新冠疫情的影响

新冠疫情对抗癫痫药物（AED）市场产生了负面影响，主要原因是神经科门诊就诊量减少、药品供应链中断以及医疗服务获取受限。然而，自2022年以来，神经科门诊量已逐渐增加，处方量也呈现復苏趋势。因此，预计该市场将在2026年至2034年间恢復到疫情前的成长轨道。

市场趋势

对第三代抗癫痫药物的关注度日益提高

影响市场的一个关键趋势是，人们越来越关注旨在解决抗药性和副作用等未满足需求的第三代抗癫痫药物。第二代药物的专利到期为製药公司开发创新疗法和仿製药提供了机会。

例如，卫材株式会社正积极拓展其癫痫药物产品组合，推出Fycompa（吡崙帕奈）的新剂型，包括于2024年1月在日本获批的注射剂型，旨在为无法耐受口服药物的患者提供更多治疗选择。

市场成长驱动因素

核准药物数量不断增加

儘管目前市面上的抗癫痫药物（AED）种类繁多，但仍有约三分之一的患者会出现抗药性或不耐受，这促使生产商加大研发投入。美国食品药物管理局（FDA）和加拿大卫生部等监管机构正在批准新的治疗方法，并推动创新。

例如，2023年6月，XCOPRI（塞诺巴酯片）在加拿大获准作为部分性发作癫痫的辅助治疗药物，从而促进了市场扩张。

政府支持

政府投资和教育活动正在加速市场成长。澳洲、印度和中国等国在癫痫管理方面的医疗保健支出，正在改善患者获得药物的途径，并促进抗癫痫药物（AEDs）在全球的普及。

限制因子

药物供应短缺

限制市场成长的主要挑战之一是抗癫痫药物短缺，尤其是在欧洲。英国脱欧带来的不确定性以及关于瑞士药品储备义务的讨论正在扰乱供应链。药品储备和供应可能会对治疗的连续性产生负面影响，并抑制市场扩张。

市场区隔分析

依药物代数

• 到2026年，第二代药物将主导市场，占39.87%的市场占有率，这主要得益于Lyrica和Keppra等重磅药物的推动。
• 由于价格实惠且具有长期临床应用价值，第一代药物仍占重要地位。
• 由于治疗范围更广、副作用更少，预计第三代药物将实现最快的增长速度。

依分销管道

• 在先进的基础设施和保险覆盖的支持下，医院药局将在2026年占50.70%的市场占有率。
• 由于就医便利性和远距医疗的普及，预计零售药局和线上药局将稳定成长。

区域概况

• 北美：预计到 2025 年市场规模将达到 86.3 亿美元，强劲的研发投入和教育计画将推动成长。美国市场预计到 2026 年将达到 72.7 亿美元。
• 欧洲：儘管面临供应挑战，但监管批准的增加正在支撑成长。
• 亚太地区：由于癫痫盛行率上升以及中国、印度和日本医疗保健服务的改善，该地区正在快速成长。
• 拉丁美洲、中东和非洲：由于医疗保健基础设施的改善，预计成长将较为温和。

目录

第一章：引言

第二章：摘要整理

第三章：市场动态

• 市场驱动因素
• 市场限制因素
• 市场机遇
• 市场趋势

第四章：关键考虑因素

• 主要国家和地区癫痫盛行率（2025 年）
• 主要公司新产品发布
• 产品线分析
• 抗癫痫药物市场面临的挑战：概述
• 主要产业趋势：併购与合作
• 新冠疫情的影响市场

第五章 全球抗癫痫药物 (AED) 市场分析：洞察与预测 (2021-2034)

• 市场分析、洞察与预测：依药物代数划分
  • 第一代
  • 第二代
  • 第三代
• 市场分析、洞察与预测：依通路划分
  • 医院药房
  • 零售药房
  • 线上药房
• 市场分析、洞察与预测：依地区划分
  • 北美
  • 欧洲
  • 亚太地区
  • 拉丁美洲
  • 中东和非洲

第六章 北美抗癫痫药物 (AED) 市场分析：洞察与预测（2021-2034）

• 依国家划分
  • 美国
  • 加拿大

第七章：欧洲抗癫痫药物（AED）市场分析：洞察与预测（2021-2034）

• 依国家划分
  • 英国
  • 德国
  • 法国
  • 义大利
  • 西班牙
  • 斯堪的纳维亚
  • 欧洲其他地区

第八章：亚太地区抗癫痫药物（AED）市场分析：洞察与预测（2021-2034）

• 依国家/地区
  • 日本
  • 中国
  • 印度
  • 澳大利亚
  • 东南亚
  • 亚太其他地区

第九章：拉丁美洲抗癫痫药物 (AED) 市场分析：洞察与预测 (2021-2034)

• 依国家划分
  • 巴西
  • 墨西哥
  • 拉丁美洲其他地区

第十章：中东与非洲抗癫痫药物 (AED) 市场分析：洞察与预测 (2021-2034)

• 依国家划分
  • 海湾合作委员会 (GCC) 国家
  • 南非
  • 中东其他地区非洲

第十一章 竞争分析

• 全球市占率分析（2025）
• 公司简介
  • Pfizer Inc.
  • UCB S.A.
  • GSK plc.
  • H. Lundbeck A/S
  • Eisai Co., Ltd.
  • Sanofi
  • Sunovion Pharmaceuticals Inc.
  • Jazz Pharmaceuticals, Inc.

Growth Factors of antiepileptic drugs (AED) Market

The global antiepileptic drugs (AED) market is witnessing steady growth due to the rising prevalence of epilepsy worldwide, increasing awareness regarding neurological disorders, and continuous advancements in drug development. According to Fortune Business Insights, the market was valued at USD 17.82 billion in 2025 and is projected to grow from USD 18.57 billion in 2026 to USD 27.57 billion by 2034, registering a CAGR of 5.10% during the forecast period (2026-2034).

North America dominated the global AED market in 2025, accounting for a 48.40% market share, supported by higher diagnosis rates, strong reimbursement policies, and frequent regulatory approvals for novel epilepsy drugs.

Market Drivers

Epilepsy is one of the most prevalent neurological disorders globally, characterized by recurrent seizures, loss of consciousness, and behavioral disturbances. According to the World Health Organization (WHO, 2023), approximately 50 million people worldwide are affected by epilepsy, with nearly 80% residing in low- and middle-income countries (LMICs). This high disease burden creates a substantial demand for effective and long-term antiepileptic therapies.

The growing prevalence of epilepsy places a significant economic burden on healthcare systems, driving governments and pharmaceutical companies to expand access to treatment. In response, market players are focusing on developing target-specific drugs with improved efficacy and reduced side effects, which is positively influencing market growth.

Impact of COVID-19

The COVID-19 pandemic negatively impacted the AED market, primarily due to reduced patient visits to neurological clinics, disruptions in drug supply chains, and limited access to healthcare services. However, from 2022 onwards, neurological consultations gradually increased, restoring prescription volumes. As a result, the market is expected to regain its pre-pandemic growth trajectory during 2026-2034.

Market Trends

Rising Focus on Third-Generation Antiepileptic Drugs

A key trend shaping the market is the growing emphasis on third-generation antiepileptic drugs, designed to address unmet clinical needs such as drug resistance and adverse effects. Patent expirations of second-generation drugs have created opportunities for pharmaceutical companies to develop both innovative therapies and generics.

For instance, Eisai Co., Ltd. has actively expanded its epilepsy portfolio by launching new formulations of Fycompa (perampanel), including an injection formulation approved in January 2024 in Japan, enhancing treatment options for patients unable to take oral medications.

Market Growth Factors

Increasing Product Approvals

Despite the availability of numerous AEDs, nearly one-third of patients experience drug resistance or intolerability, prompting manufacturers to intensify R&D activities. Regulatory bodies such as the U.S. FDA and Health Canada have been approving new therapies, encouraging innovation.

For example, in June 2023, XCOPRI (cenobamate tablets) received regulatory approval in Canada for adjunctive treatment of partial-onset seizures, supporting market expansion.

Government Support

Government investments and awareness initiatives are accelerating market growth. Public healthcare expenditure on epilepsy management, as seen in countries like Australia, India, and China, is improving patient access to medications and driving adoption of AEDs globally.

Restraining Factors

Drug Supply Shortages

One of the major challenges restraining market growth is the shortage of antiepileptic drugs, particularly in Europe. Brexit-related uncertainties in the U.K. and mandatory drug reserve discussions in Switzerland have disrupted supply chains. Medicine stockpiling and limited availability can negatively affect treatment continuity, thereby restraining market expansion.

Segmentation Analysis

By Drug Generation

• Second-generation drugs dominated the market in 2026, accounting for 39.87% share, driven by blockbuster drugs such as Lyrica and Keppra.
• First-generation drugs maintained a notable presence due to affordability and long-term clinical use.
• Third-generation drugs are expected to grow at the fastest rate due to broader therapeutic benefits and fewer adverse effects.

By Distribution Channel

• Hospital pharmacies dominated the market in 2026 with a 50.70% share, supported by advanced infrastructure and reimbursement coverage.
• Retail and online pharmacies are expected to grow steadily due to improved accessibility and telemedicine adoption.

Regional Insights

• North America: Valued at USD 8.63 billion in 2025, driven by strong R&D investment and awareness programs. The U.S. market is projected to reach USD 7.27 billion by 2026.
• Europe: Growth supported by increasing regulatory approvals despite supply challenges.
• Asia Pacific: Fast-growing region due to rising epilepsy prevalence and improved healthcare access in China, India, and Japan.
• Latin America & Middle East & Africa: Moderate growth driven by developing healthcare infrastructure.

Competitive Landscape

The market is highly consolidated, with key players including Pfizer Inc., UCB S.A., GSK plc., Eisai Co., Ltd., and Sanofi. While Pfizer's Lyrica has historically dominated the market, patent expiry has intensified competition from generics and newer therapies.

Conclusion

The global antiepileptic drugs (AED) market is set for steady growth through 2034, supported by rising epilepsy prevalence, continuous drug innovation, and favorable regulatory frameworks. With the market expected to reach USD 27.57 billion by 2034, sustained R&D investments, government support, and improved access to treatment will be critical in addressing unmet patient needs and driving long-term market expansion.

Segmentation By Drug Generation

• First Generation
• Second Generation
• Third Generation

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region

• North America (By Drug Generation, By Distribution Channel, and By Country)
  • U.S.
  • Canada
• Europe (By Drug Generation, By Distribution Channel, and By Country/Sub-Region)
  • U.K.
  • Germany
  • France
  • Italy
  • Spain
  • Scandinavia
  • Rest of Europe
• Asia Pacific (By Drug Generation, By Distribution Channel, and By Country/Sub-Region)
  • Japan
  • China
  • India
  • Australia
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America (By Drug Generation, By Distribution Channel, and By Country/Sub-Region)
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa (By Drug Generation, By Distribution Channel, and By Country/Sub-Region)
  • GCC
  • South Africa
  • Rest of the Middle East & Africa

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Prevalence of Epilepsy, By Key Countries/ Regions, 2025
• 4.2. New Product Launches, By Key Players
• 4.3. Pipeline Analysis
• 4.4. Overview of Challenges Faced in the Antiepileptic Drugs Market
• 4.5. Key Industry Developments - Mergers, Acquisitions, and Partnerships
• 4.6. Impact of COVID-19 on the Market

5. Global Antiepileptic Drugs (AED) Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Drug Generation
  • 5.1.1. First Generation
  • 5.1.2. Second Generation
  • 5.1.3. Third Generation
• 5.2. Market Analysis, Insights and Forecast - By Distribution Channel
  • 5.2.1. Hospital Pharmacies
  • 5.2.2. Retail Pharmacies
  • 5.2.3. Online Pharmacies
• 5.3. Market Analysis, Insights and Forecast - By Region
  • 5.3.1. North America
  • 5.3.2. Europe
  • 5.3.3. Asia Pacific
  • 5.3.4. Latin America
  • 5.3.5. Middle East & Africa

6. North America Antiepileptic Drugs (AED) Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Drug Generation
  • 6.1.1. First Generation
  • 6.1.2. Second Generation
  • 6.1.3. Third Generation
• 6.2. Market Analysis, Insights and Forecast - By Distribution Channel
  • 6.2.1. Hospital Pharmacies
  • 6.2.2. Retail Pharmacies
  • 6.2.3. Online Pharmacies
• 6.3. Market Analysis, Insights and Forecast - By Country
  • 6.3.1. U.S.
  • 6.3.2. Canada

7. Europe Antiepileptic Drugs (AED) Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Drug Generation
  • 7.1.1. First Generation
  • 7.1.2. Second Generation
  • 7.1.3. Third Generation
• 7.2. Market Analysis, Insights and Forecast - By Distribution Channel
  • 7.2.1. Hospital Pharmacies
  • 7.2.2. Retail Pharmacies
  • 7.2.3. Online Pharmacies
• 7.3. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 7.3.1. U.K.
  • 7.3.2. Germany
  • 7.3.3. France
  • 7.3.4. Italy
  • 7.3.5. Spain
  • 7.3.6. Scandinavia
  • 7.3.7. Rest of Europe

8. Asia Pacific Antiepileptic Drugs (AED) Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Drug Generation
  • 8.1.1. First Generation
  • 8.1.2. Second Generation
  • 8.1.3. Third Generation
• 8.2. Market Analysis, Insights and Forecast - By Distribution Channel
  • 8.2.1. Hospital Pharmacies
  • 8.2.2. Retail Pharmacies
  • 8.2.3. Online Pharmacies
• 8.3. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 8.3.1. Japan
  • 8.3.2. China
  • 8.3.3. India
  • 8.3.4. Australia
  • 8.3.5. Southeast Asia
  • 8.3.6. Rest of Asia Pacific

9. Latin America Antiepileptic Drugs (AED) Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Drug Generation
  • 9.1.1. First Generation
  • 9.1.2. Second Generation
  • 9.1.3. Third Generation
• 9.2. Market Analysis, Insights and Forecast - By Distribution Channel
  • 9.2.1. Hospital Pharmacies
  • 9.2.2. Retail Pharmacies
  • 9.2.3. Online Pharmacies
• 9.3. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 9.3.1. Brazil
  • 9.3.2. Mexico
  • 9.3.3. Rest of Latin America

10. Middle East & Africa Antiepileptic Drugs (AED) Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Market Analysis, Insights and Forecast - By Drug Generation
  • 10.1.1. First Generation
  • 10.1.2. Second Generation
  • 10.1.3. Third Generation
• 10.2. Market Analysis, Insights and Forecast - By Distribution Channel
  • 10.2.1. Hospital Pharmacies
  • 10.2.2. Retail Pharmacies
  • 10.2.3. Online Pharmacies
• 10.3. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 10.3.1. GCC
  • 10.3.2. South Africa
  • 10.3.3. Rest of Middle East & Africa

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2025)
• 11.2. Company Profiles
  • 11.2.1. Pfizer Inc.
    • 11.2.1.1. Overview
    • 11.2.1.2. Products & Services
    • 11.2.1.3. SWOT Analysis
    • 11.2.1.4. Recent Developments
    • 11.2.1.5. Strategies
    • 11.2.1.6. Financials (Based on Availability)
  • 11.2.2. UCB S.A.
    • 11.2.2.1. Overview
    • 11.2.2.2. Products & Services
    • 11.2.2.3. SWOT Analysis
    • 11.2.2.4. Recent Developments
    • 11.2.2.5. Strategies
    • 11.2.2.6. Financials (Based on Availability)
  • 11.2.3. GSK plc.
    • 11.2.3.1. Overview
    • 11.2.3.2. Products & Services
    • 11.2.3.3. SWOT Analysis
    • 11.2.3.4. Recent Developments
    • 11.2.3.5. Strategies
    • 11.2.3.6. Financials (Based on Availability)
  • 11.2.4. H. Lundbeck A/S
    • 11.2.4.1. Overview
    • 11.2.4.2. Products & Services
    • 11.2.4.3. SWOT Analysis
    • 11.2.4.4. Recent Developments
    • 11.2.4.5. Strategies
    • 11.2.4.6. Financials (Based on Availability)
  • 11.2.5. Eisai Co., Ltd.
    • 11.2.5.1. Overview
    • 11.2.5.2. Products & Services
    • 11.2.5.3. SWOT Analysis
    • 11.2.5.4. Recent Developments
    • 11.2.5.5. Strategies
    • 11.2.5.6. Financials (Based on Availability)
  • 11.2.6. Sanofi
    • 11.2.6.1. Overview
    • 11.2.6.2. Products & Services
    • 11.2.6.3. SWOT Analysis
    • 11.2.6.4. Recent Developments
    • 11.2.6.5. Strategies
    • 11.2.6.6. Financials (Based on Availability)
  • 11.2.7. Sunovion Pharmaceuticals Inc.
    • 11.2.7.1. Overview
    • 11.2.7.2. Products & Services
    • 11.2.7.3. SWOT Analysis
    • 11.2.7.4. Recent Developments
    • 11.2.7.5. Strategies
    • 11.2.7.6. Financials (Based on Availability)
  • 11.2.8. Jazz Pharmaceuticals, Inc.
    • 11.2.8.1. Overview
    • 11.2.8.2. Products & Services
    • 11.2.8.3. SWOT Analysis
    • 11.2.8.4. Recent Developments
    • 11.2.8.5. Strategies
    • 11.2.8.6. Financials (Based on Availability)

List of Tables

• Table 1: Global Antiepileptic Drugs Market Revenue (USD billion) Forecast, by Drug Generation, 2021-2034
• Table 2: Global Antiepileptic Drugs Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
• Table 3: Global Antiepileptic Drugs Market Revenue (USD billion) Forecast, by Region, 2021-2034
• Table 4: North America Antiepileptic Drugs Market Revenue (USD billion) Forecast, by Drug Generation, 2021-2034
• Table 5: North America Antiepileptic Drugs Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
• Table 6: North America Antiepileptic Drugs Market Revenue (USD billion) Forecast, By Country, 2021-2034
• Table 7: Europe Antiepileptic Drugs Market Revenue (USD billion) Forecast, by Drug Generation, 2021-2034
• Table 8: Europe Antiepileptic Drugs Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
• Table 9: Europe Antiepileptic Drugs Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
• Table 10: Asia Pacific Antiepileptic Drugs Market Revenue (USD billion) Forecast, by Drug Generation, 2021-2034
• Table 11: Asia Pacific Antiepileptic Drugs Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
• Table 12: Asia Pacific Antiepileptic Drugs Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
• Table 13: Latin America Antiepileptic Drugs Market Revenue (USD billion) Forecast, by Drug Generation, 2021-2034
• Table 14: Latin America Antiepileptic Drugs Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
• Table 15: Latin America Antiepileptic Drugs Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
• Table 16: Middle East & Africa Antiepileptic Drugs Market Revenue (USD billion) Forecast, by Drug Generation, 2021-2034
• Table 17: Middle East & Africa Antiepileptic Drugs Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
• Table 18: Middle East & Africa Antiepileptic Drugs Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034

List of Figures

• Figure 1: Global Antiepileptic Drugs Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
• Figure 2: Global Antiepileptic Drugs Market Value Share (%), by Drug Generation, 2025 & 2034
• Figure 3: Global Antiepileptic Drugs Market Value Share (%), by Distribution Channel, 2025 & 2034
• Figure 4: Global Antiepileptic Drugs Market Value (USD billion), by Region, 2025 & 2034
• Figure 5: North America Antiepileptic Drugs Market Value (USD billion), by Drug Generation, 2025 & 2034
• Figure 6: North America Antiepileptic Drugs Market Value Share (%), by Drug Generation, 2025
• Figure 7: North America Antiepileptic Drugs Market Value (USD billion), by Distribution Channel, 2025 & 2034
• Figure 8: North America Antiepileptic Drugs Market Value Share (%), by Distribution Channel, 2025
• Figure 9: North America Antiepileptic Drugs Market Value (USD billion), By Country, 2025 & 2034
• Figure 10: North America Antiepileptic Drugs Market Value Share (%), By Country, 2025
• Figure 11: Europe Antiepileptic Drugs Market Value (USD billion), by Drug Generation, 2025 & 2034
• Figure 12: Europe Antiepileptic Drugs Market Value Share (%), by Drug Generation, 2025
• Figure 13: Europe Antiepileptic Drugs Market Value (USD billion), by Distribution Channel, 2025 & 2034
• Figure 14: Europe Antiepileptic Drugs Market Value Share (%), by Distribution Channel, 2025
• Figure 15: Europe Antiepileptic Drugs Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
• Figure 16: Europe Antiepileptic Drugs Market Value Share (%), By Country/ Sub-region, 2025
• Figure 17: Asia Pacific Antiepileptic Drugs Market Value (USD billion), by Drug Generation, 2025 & 2034
• Figure 18: Asia Pacific Antiepileptic Drugs Market Value Share (%), by Drug Generation, 2025
• Figure 19: Asia Pacific Antiepileptic Drugs Market Value (USD billion), by Distribution Channel, 2025 & 2034
• Figure 20: Asia Pacific Antiepileptic Drugs Market Value Share (%), by Distribution Channel, 2025
• Figure 21: Asia Pacific Antiepileptic Drugs Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
• Figure 22: Asia Pacific Antiepileptic Drugs Market Value Share (%), By Country/ Sub-region, 2025
• Figure 23: Latin America Antiepileptic Drugs Market Value (USD billion), by Drug Generation, 2025 & 2034
• Figure 24: Latin America Antiepileptic Drugs Market Value Share (%), by Drug Generation, 2025
• Figure 25: Latin America Antiepileptic Drugs Market Value (USD billion), by Distribution Channel, 2025 & 2034
• Figure 26: Latin America Antiepileptic Drugs Market Value Share (%), by Distribution Channel, 2025
• Figure 27: Latin America Antiepileptic Drugs Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
• Figure 28: Latin America Antiepileptic Drugs Market Value Share (%), By Country/ Sub-region, 2025
• Figure 29: Middle East & Africa Antiepileptic Drugs Market Value (USD billion), by Drug Generation, 2025 & 2034
• Figure 30: Middle East & Africa Antiepileptic Drugs Market Value Share (%), by Drug Generation, 2025
• Figure 31: Middle East & Africa Antiepileptic Drugs Market Value (USD billion), by Distribution Channel, 2025 & 2034
• Figure 32: Middle East & Africa Antiepileptic Drugs Market Value Share (%), by Distribution Channel, 2025
• Figure 33: Middle East & Africa Antiepileptic Drugs Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
• Figure 34: Middle East & Africa Antiepileptic Drugs Market Value Share (%), By Country/ Sub-region, 2025
• Figure 35: Global Antiepileptic Drugs Market Share Analysis (%), By Company, 2025